General Administration of Financial Supervision: Help boost consumer support and expand bulk consumption, service consumption and new consumption. The Party Committee of the State Financial Supervision and Administration held a meeting to convey the spirit of studying the Central Economic Work Conference. The meeting requested that the real economy should be better served to help boost consumption and support the expansion of bulk consumption, service consumption and new consumption. Strengthen the financing guarantee for investment and effectively serve the "double" and "two new". Expand the pilot of equity investment of financial asset investment companies in an orderly manner. Do a solid job in supporting the financing coordination mechanism of small and micro enterprises. Increase financial support for foreign trade enterprises and strengthen export credit insurance and credit services. Actively guide banks and insurance institutions to reduce costs and increase efficiency, broaden capital replenishment channels, and improve their sustainable development capabilities. Promote high-level financial openness with higher standards and greater efforts, and attract more foreign financial institutions and long-term capital to set up businesses in China.On December 13th, Jiangsu Securities Regulatory Bureau issued an announcement that Yan Zhen had privately accepted the entrustment of customers to buy and sell securities during his tenure in the securities business department of Xuzhou Jianguo West Road of CITIC Securities (formerly known as the securities business department of Xuzhou Jiefang South Road of CITIC Securities). In violation of regulations, she was supervised to issue a warning letter and recorded it in the integrity file of the securities and futures market.The EUR/USD of the euro against the US dollar rose by 0.50% in the day and is now reported at 1.0518.
Kexing launched the world's first phase III clinical study of bivalent inactivated enterovirus vaccine. On December 13th, the first volunteer was enrolled in the phase III clinical study of bivalent inactivated enterovirus vaccine developed by Beijing Kexing Biological Products Co., Ltd., a subsidiary of Kexing Holding Biotechnology Co., Ltd. (hereinafter referred to as "Kexing"). The vaccine is used to prevent hand, foot and mouth disease caused by enterovirus 71 (EV71) and coxsackie virus 16 (CA16). A multicenter, randomized, double-blind, controlled study design was adopted in this phase III clinical study to evaluate the protective efficacy, safety and immunogenicity of the vaccine in children aged 6-71 months.Market News: The United Arab Emirates will restrict oil transportation in the case of OPEC+promoting compliance with quotas.Daye shares: the proposed acquisition of 100% equity of Al-Kogerte GmbH constitutes a major asset restructuring. Daye shares announced that the company intends to acquire 100% equity of Al-Kogerte GmbH in cash through its wholly-owned subsidiary RUNBO INT PTE.LTD, which constitutes a major asset restructuring of the company.
Russian Ministry of Defence: Russian armed forces occupied seven settlements in one week.In November, the real effective interest rate of the Russian ruble decreased by 1.6% from the previous month.Donghua Technology: Inner Mongolia New Materials, a holding subsidiary, signed a product sales contract with Yulin Chemical of Shaanxi Coal Group. Donghua Technology announced that China National Chemical New Materials Co., Ltd., a holding subsidiary, plans to sign a Product Sales Contract with Yulin Chemical Co., Ltd. of Shaanxi Coal Group, stipulating that Yulin Chemical will sell ethylene glycol and by-products produced by Inner Mongolia New Materials. The contract is from October 20, 2024 to December 31, 2025. Product prices are divided into temporary pricing and settlement price, and are priced according to the principle of marketization. From the beginning of 2024 to the disclosure date, the Company had related transactions with Yulin Chemical and its concerted parties, mainly to provide engineering services to Yulin Chemical and its concerted parties, with the related transactions amounting to 438 million yuan.